skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

Products

もっと見る

もっと見る

46 Total results for product and free and sample content found

Generics Bulletin: ジェネリック&バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Nov 2020

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Stockwatch: The First Coronavirus Earnings Season May Come Early

08 Apr 2020

andy-smith

The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.

Topic Coronavirus

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

By Andy Smith 30 Jan 2020

Stockwatch_Earnings_Season_Catches_An_Early_Cold

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

Topic Business Strategies Coronavirus Sales Earnings Vaccines

ターゲット市場の実像をつかむ

Allergan uses Native American tribe’s sovereign immunity to delay generic entry

By Zara Fulton 07 Oct 2017

Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.

Topic Company Analysis

ターゲット市場の実像をつかむ

Gilead expands into CAR-T therapy with $11.9bn purchase of Kite Pharmaceuticals

By Oliver Spray 07 Oct 2017

Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.

Topic Company Analysis

ターゲット市場の実像をつかむ

Xtandi will have first-mover advantage in non-metastatic prostate cancer setting

By Edward Thomason 07 Oct 2017

Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier

Topic Cancer

ターゲット市場の実像をつかむ

Alnylam and partner Sanofi deliver on their RNAi promise with groundbreaking results in rare polyneuropathy condition

By Zara Fulton 07 Oct 2017

Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.

Topic BioPharmaceutical

ターゲット市場の実像をつかむ

Ocrevus FDA approval marks watershed moment for MS market

02 Apr 2017

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).

Topic FDA Multiple Sclerosis

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。


新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。

お問合せの際はフォームまたは下記メールアドレスをご利用頂くか、営業担当者の携帯電話までご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
Eメール:
inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。